In short
This article discusses the clinical trials of GAd20-209-FSP, a genetic vaccine being studied for the treatment of advanced microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. The trials aim to assess the safety, tolerability, and effectiveness of this innovative therapy when combined with pembrolizumab, an immunotherapy drug.
At a glance
- Study Type
- Phase I/II, Multi-center, Open-Label Study
- Treatment
- GAd20-209-FSP genetic vaccine + pembrolizumab
- Target Condition
- Advanced MSI-H or dMMR Colorectal Cancer
- Primary Objective
- Assess anti-tumor activity (ORR)
- Secondary Objectives
- Safety, tolerability, BOR, DoR, PFS
- Key Eligibility Criteria
- Age ≥18, MSI-H/dMMR status, adequate organ function
- Administration Route
- Intramuscular injection
What is GAD20-209-FSP-A3?
GAD20-209-FSP-A3 is part of a genetic vaccine called Nous-209, which is being developed to treat certain types of advanced cancer. This vaccine is made up of four components, including GAD20-209-FSP-A1, GAD20-209-FSP-A2, GAD20-209-FSP-A3, and GAD20-209-FSP-A4. Together, these components form a solution that is injected into the muscle to stimulate the immune system against cancer cells.
How Does It Work?
The GAD20-209-FSP-A3 vaccine is based on a modified adenovirus, which is a type of virus that has been engineered to deliver genetic material into the body. This genetic material encodes for 209 Frame Shift Peptides (FSPs), which are abnormal proteins found in certain types of cancer cells.
When injected, the vaccine teaches the immune system to recognize these abnormal proteins, potentially helping it to identify and attack cancer cells that produce them. This approach is known as immunotherapy, as it uses the body's own immune system to fight cancer.
What Conditions Does It Treat?
The GAD20-209-FSP-A3 vaccine is being studied for the treatment of advanced colorectal cancer with specific characteristics. Specifically, it targets:
- Locally advanced unresectable or metastatic colorectal cancer: This means cancer that has spread beyond the colon or rectum and cannot be removed surgically.
- Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors: These are specific genetic features found in some colorectal cancers that make them potentially more responsive to immunotherapy.
Clinical Trial Information
The GAD20-209-FSP-A3 vaccine is currently being studied in a clinical trial. Here are some key points about the trial:
- It's a Phase I/II trial, which means it's testing both the safety and effectiveness of the treatment.
- The trial is open-label, meaning both patients and doctors know which treatment is being given.
- The vaccine is being studied in combination with another drug called pembrolizumab, which is an existing immunotherapy treatment.
- The main goal is to see if the combination of the vaccine and pembrolizumab can shrink tumors or slow down cancer growth.
Eligibility Criteria
To participate in the trial, patients must meet certain criteria. Some key eligibility requirements include:
- Being 18 years or older
- Having advanced colorectal cancer that is MSI-H or dMMR
- Having cancer that can be measured on scans
- Being in relatively good overall health
- Not having certain other medical conditions or previous treatments that could interfere with the study
Potential Benefits and Risks
As with any experimental treatment, there are potential benefits and risks to consider:
Potential benefits:
- The treatment may help slow down or stop cancer growth
- It may shrink tumors
- It could potentially improve survival for patients with advanced colorectal cancer
Potential risks:
- Side effects from the vaccine or pembrolizumab
- The treatment may not work as well as hoped
- There may be unknown risks, as this is an experimental treatment
It's important to discuss these potential benefits and risks thoroughly with a healthcare provider before considering participation in the clinical trial.